氰胍佐旦
氰胍佐旦 性质
熔点 | 268-268.9 °C(lit.) |
---|---|
密度 | 1.31±0.1 g/cm3(Predicted) |
储存条件 | 2-8°C |
溶解度 | DMSO:>5 mg/mL,易溶 |
酸度系数(pKa) | 13.71±0.60(Predicted) |
形态 | 固体 |
颜色 | 白色 |
氰胍佐旦 用途与合成方法
IC50: 117 nM (phosphodiesterase III)
Siguazodan selectively inhibits the major cyclic AMP-hydrolysing PDE in human platelet supernatants. The inhibited enzyme has been variously termed cyclic GMP-inhibited PDE or PDE-III. In platelet-rich plasma (PRP), Siguazodan inhibits U46619-induced aggregation more potently than that induced by adenosine 5'-diphosphate (ADP), and collagen. Treatment of the PRP with Aspirin has no effect on the potency of Siguazodan. In washed platelets, Siguazodan increases cyclic AMP levels and reduces cytoplasmic free calcium. ADP decreases the ability of Siguazodan to raise cyclic AMP and this may explain its lower potency in inhibiting responses to ADP. Siguazodan has anti-platelet actions over the same concentration range that it is an inotrope and vasodilator.
Siguazodan is a potent, selective inhibitor of phosphodiesterase III that has positive inotropic and vasodilating actions in various laboratory animals and is orally active with a long duration of action in conscious dogs.
氰胍佐旦 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-19026 | 氰胍佐旦 | 115344-47-3 | 5mg | 1000 |
2024-11-08 | HY-19026 | 10 mM * 1 mLin DMSO | 1100 |